Status:
RECRUITING
Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
Lead Sponsor:
Barnet Dulaney Perkins Eye Centers
Collaborating Sponsors:
Alcon, a Novartis Company
Conditions:
Open-Angle Glaucoma
Eligibility:
All Genders
18+ years
Brief Summary
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Detailed Description
The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
Eligibility Criteria
Inclusion
- Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
- have Glaucoma
Exclusion
- Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
- Patients with refractory CME or CME persisting 3 months or more post-operatively
- Patients with incomplete IOP, medication logs or VF data within post-operative period
- Prior incisional surgery or MIGS
Key Trial Info
Start Date :
March 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06953349
Start Date
March 31 2025
End Date
December 31 2025
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnet Dulaney Perkins Eye Center
Mesa, Arizona, United States, 85206